Off-label and non-classical prescriptions of antipsychotic agents in ordinary in-patient practice

被引:42
作者
Barbui, C
Ciuna, A
Nosé, M
Patten, SB
Stegagno, M
Burti, L
Amaddeo, F
Tansella, M
机构
[1] Univ Verona, Dept Med & Publ Hlth, Sect Psychiat, I-37100 Verona, Italy
[2] Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada
[3] Univ Calgary, Dept Psychiat, Calgary, AB T2N 1N4, Canada
关键词
antipsychotic drugs; psychosis; clinical practice;
D O I
10.1111/j.1600-0447.2003.00283.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To estimate the proportion of off-label prescriptions of antipsychotics (APs) in ordinary in-patient practice. Method: From the South-Verona Psychiatric Case Register all admissions to the in-patient unit during 2001-02 were extracted. Prescriptions of APs were defined off-label when dispensed outside the licensed indications. In addition, the proportion of 'non-classical prescriptions' was calculated. Results: During the 2 years surveyed AP agents were prescribed in 311 cases. Nearly 50% of second-generation AP prescriptions were for an off-label indication. In contrast, <15% of first-generation AP prescriptions were for an off-label indication. About 30% of first- and second-generation agents were prescribed for a non-classical indication. Conclusion: Approved labels for second-generation AP agents cover a much narrower range of indications than any of the first-generation agents, and this explains the higher proportion of off-label prescriptions. In contrast, the everyday use of first- and second-generation APs cover a similar range of clinical indications.
引用
收藏
页码:275 / 278
页数:4
相关论文
共 15 条
[1]   Accessibility and pathways to psychiatric care in a community-based mental health system [J].
Amaddeo, F ;
Zambello, F ;
Tansella, M ;
Thornicroft, G .
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2001, 36 (10) :500-507
[2]  
AMADDEO F, 1997, ACTA PSYCHIAT SCAND, V95, P185
[3]   Varying and "atypical" indications for atypical antipsychotics [J].
Barbui, C ;
Tansella, M ;
Garattini, S .
PSYCHOPHARMACOLOGY, 2003, 169 (02) :205-206
[4]   Regulatory issues in Europe [J].
Barbui, C ;
Guaiana, G ;
Garatini, S .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2001, 21 (06) :545-548
[5]   Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use [J].
Fleischhacker, WW .
PSYCHOPHARMACOLOGY, 2003, 169 (02) :207-210
[6]   Patterns of neuroleptic drug prescription:: a national cross-sectional survey of a random sample of French psychiatrists [J].
Fourrier, A ;
Gasquet, I ;
Allicar, MP ;
Bouhassira, M ;
Lépine, JP ;
Bégaud, B .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (01) :80-86
[7]   Efficacy, safety and cost of new drugs acting on the central nervous system [J].
Garattini, S ;
Bertele, V .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (01) :79-84
[8]   Adjusting Europe's drug regulation to public health needs [J].
Garattini, S ;
Bertele, V .
LANCET, 2001, 358 (9275) :64-67
[9]   Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis [J].
Geddes, J ;
Freemantle, N ;
Harrison, P ;
Bebbington, P .
BRITISH MEDICAL JOURNAL, 2000, 321 (7273) :1371-1376
[10]   Cross-cultural differences in the conceptualisation of patients' satisfaction with psychiatric services - Content validity of the English version of the Verona Service Satisfaction Scale [J].
Henderson, C ;
Hales, H ;
Ruggeri, M .
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2003, 38 (03) :142-148